Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patien
2024年4月9日 - 9:11PM
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular
Templates,” or “MTEM”), a clinical-stage biopharmaceutical company
focused on the discovery and development of proprietary targeted
biologic therapeutics, engineered toxin bodies (“ETBs”), to create
novel therapies with potent differentiated mechanisms of action for
cancer, today announced that MTEM will present a poster,
“First-in-human, dose escalation and expansion study of MT-6402, a
novel engineered toxin body (ETB) targeting PD-L1, in patients with
PD-L1 expressing relapsed/refractory advanced solid tumors: Interim
Data,” at the 2024 American Association for Cancer Research Annual
Meeting taking place in San Diego, CA, and also announced
monotherapy response activity in Head and Neck Cancer.
The poster highlighted the following findings
from the phase I dose-escalation study of MT-6402:
- MT-6402 has been well tolerated with
no drug-related Grade 4 or Grade 5 adverse events observed
- MT-6402 acts uniquely from other
approved checkpoint agents. MT-6402 depletes immunosuppressive
PD-L1+ immune cells and tumor cells, activates a
T-effector phenotype, and remodels the tumor microenvironment to
restore T-cell surveillance of the tumor.
- An early monotherapy efficacy signal
in head and neck squamous cell carcinoma (HNSCC) was identified.
Nine patients with recurrent and metastatic heavily pre-treated and
checkpoint-experienced HNSCC were treated in the phase I dose
escalation of which two patients have confirmed durable PRs.
- 2 of the 9 patients with HNSCC
treated with MT-6402 showed confirmed partial responses (one
response was unconfirmed at the time of the poster’s submission but
has subsequently been confirmed). The patients remain on study at
cycles 19 and 10, respectively (one cycle = 4 weeks), demonstrating
the potential for durable monotherapy activity with MT-6402.
- Both patients had
low PD-L1 tumor expression and had progressed after multiple lines
of therapy including checkpoint. Additionally, both patients showed
unique pharmacodynamic effects consistent with tumor
microenvironment remodeling including reduction in myeloid derived
suppressor cells (MDSCs) and modulation of VEGF.
- Tumor reductions
were observed in other patients including an unconfirmed PR.
“We are excited to see objective responses in
heavily pre-treated, checkpoint-experienced, head and neck cancer
patients, a setting with high unmet medical need,” said CEO Eric
Poma. “The long-lasting partial responses were in patients with low
PD-L1 expression and showed concomitant increases in cytokines
associated with T-cell activation and tumor microenvironment
remodeling not seen with other checkpoint therapies. We believe the
novel mechanism of action of MT-6402 may allow for durable,
T-cell-mediated, monotherapy activity in patients who have
progressed on checkpoint therapy. Based on the preliminary signals
of single agent activity with MT-6402, an expansion study in low
PD-L1 head and neck cancer patients to further evaluate MT-6402 has
been initiated.”
AACR Presentation Title:
First-in-human, dose escalation and expansion study of MT-6402, a
novel engineered toxin body (ETB) targeting PD-L1, in patients with
PD-L1 expressing relapsed/refractory advanced solid tumors: Interim
Data Location: Section 48, Poster #19, Abstract
#CT191 Date/Time: 9am – 12:30pm PT Tuesday, April
9, 2024 The abstract will be available in the Presentations section
of MTEM’s website.
About Molecular Templates
Molecular Templates is a clinical-stage
biopharmaceutical company focused on the discovery and development
of targeted biologic therapeutics. Our proprietary drug platform
technology, known as engineered toxin bodies, or ETBs, leverages
the resident biology of a genetically engineered form of Shiga-like
Toxin A subunit to create novel therapies with potent and
differentiated mechanisms of action for cancer.
Forward-Looking
Statements This press release contains
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995 (the “Act”). Molecular Templates
disclaims any intent or obligation to update these forward-looking
statements and claims the protection of the Act’s Safe Harbor for
forward-looking statements. All statements, other than statements
of historical facts, included in this press release, including, but
not limited to those regarding strategy, future operations, the
Company’s ability to execute on its objectives, prospects, plans,
future clinical development of the Company’s product candidates,
any implication that the preliminary results, interim results, or
the results of earlier clinical trials or ongoing clinical trials
will be representative of the results of future or later clinical
trials or final results, the potential benefits, safety or efficacy
and any evaluations or judgements regarding the Company’s product
candidates, [the results of any strategic process which are
inherently uncertain at the present time] and future execution of
corporate goals. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “continue”,
“anticipate,” “potential”, “believe,” “estimate,” “appears”,
“expect,” “intend,” “plan,” “predict” and similar expressions and
their variants, as they relate to Molecular Templates may identify
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties. Actual events or results may differ materially from
those discussed in the forward-looking statements as a result of
various factors including, but not limited to the following: the
continued availability of financing on commercially reasonable
terms, whether Molecular Templates’ cash resources will be
sufficient to fund its continuing operations; the results of MTEM’s
ongoing clinical studies and the ability to effectively operate
MTEM, and those risks identified under the heading “Risk Factors”
in Molecular Templates’ filings with the Securities and Exchange
Commission (the “SEC”), including its Form 10-K for the year ended
December 31, 2023 and any subsequent reports filed with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Molecular Templates
specifically disclaims any obligation to update any forward-looking
statement, whether because of new information, future events or
otherwise.
Contacts:grace.kim@mtem.com
Molecular Templates (NASDAQ:MTEM)
過去 株価チャート
から 11 2024 まで 12 2024
Molecular Templates (NASDAQ:MTEM)
過去 株価チャート
から 12 2023 まで 12 2024